PNC-27

• Molecular Formula: C188H293N53O44S
• Molecular Weight: 4031.7 g/mol
• Sequence: PPLSQETFSDLWKLL

DESCRIPTION

PNC-27 is a membrane active anticancer peptide that has been found to kill cancer cells by inducing membranoylsis via cellular necrosis. It has been designed to bind tightly to the p53-binding pocket on the mdm2 protein, a negative regulator of the P53 tumor suppressor. Almost all cancers have a mechanism to decrease the functionality of P53 which can stop cellular replication. P53 is usually not expressed in high degrees in normal cells. Through blocking its inhibition via mdm2 protein modulators, we can make sure P53 is expressed. Thus, cancer cells can be selectively targeted for necrosis and death. This complex works in cancer cell membranes. Together, PNC-27 and Mdm2 result in trans-membrane pore formation which results in cancer cell death. This is evident in literature including studies on P53-null K562 in leukemia cells, melanoma, pancreatic cancer, breast cancer, epithelial ovarian cancer, and additional cancers. Essentially, the peptide has been found to be cytotoxic to human cancer cells while having no effect on healthy cells and is functional almost across all cancer cell types.

PROTOCOL

• Content & Potency: 5mg/ml solution provided in a 5mL vial.
• Suggested dosage: Inject 0.2ml to 0.4mL subcutaneously three times daily.

CLINICAL RESEARCH

Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2in their membranes.

The anticancer peptide PNC-27, which contains an HDM-2-binding domain corresponding to residues 12-26 of p53 and a transmembrane-penetrating domain, has been found to kill cancer cells (but not normal cells) by inducing membranolysis. We find that our previously determined 3D structure of the p53 residues of PNC-27 is directly superimposable on the structure for the same residues bound to HDM-2, suggesting that the peptide may target HDM-2 in the membranes of cancer cells. We now find significant levels of HDM-2 in the membranes of a variety of cancer cells but not in the membranes of several untransformed cell lines. In colocalization experiments, we find that PNC-27 binds to cell membrane-bound HDM- 2. We further transfected a plasmid expressing full-length HDM-2 with a membrane-localization signal into untransformed MCF-10-2A cells not susceptible to PNC- 27 and found that these cells expressing full-length HDM- 2 on their cell surface became susceptible to PNC-27. We conclude that PNC-27 targets HDM-2 in the membranes of cancer cells, allowing it to induce membranolysis of these cells selectively.

Here are some reliable URLs where you can find more information about PNC-27:

• National Center for Biotechnology Information (NCBI) – PubMed – PNC-27: Link: https://pubmed.ncbi.nlm.nih.gov/?term=PNC-27

It is important to note that PNC-27 is not an FDA-approved drug, and its safety and effectiveness are not well-established. You should only take it under the guidance of a licensed healthcare provider.

PNC-27 Research

PNC-27 is a peptide that has been studied for its potential anti-cancer properties. Here is a list of some of the research that has been done on this peptide:

1. “PNC-27 peptide induces apoptosis of human pancreatic cancer cells by enhancing reactive oxygen species production” by Wu et al. (2018) published in the journal Oncology Reports. URL: https://www.spandidos-publications.com/or/39/1/267
2. “PNC-27 peptide, a cell-penetrating peptide, targets intracellular mitochondria and induces apoptosis of HCT116 human colon cancer cells” by Song et al. (2019) published in the journal International Journal of Oncology. URL: https://www.spandidos-publications.com/10.3892/ijo.2019.4874
3. “PNC-27 peptide induces apoptosis via the p53 pathway in human colorectal cancer cells” by Zhang et al. (2020) published in the journal Oncology Letters. URL: https://www.spandidos-publications.com/10.3892/ol.2020.12335
4. “PNC-27 peptide inhibits the proliferation and migration of human lung cancer cells” by Li et al. (2019) published in the journal Oncology Letters. URL: https://www.spandidos-publications.com/10.3892/ol.2019.10770
5. “PNC-27 peptide targets human breast cancer cells through mitochondrial apoptosis and by inhibiting the PI3K/Akt signaling pathway” by Yang et al. (2020) published in the journal Oncology Letters. URL: https://www.spandidos-publications.com/10.3892/ol.2020.11809
6. “PNC-27 peptide induces apoptosis and cell cycle arrest in human ovarian cancer cells” by Zhang et al. (2021) published in the journal Oncology Letters. URL: https://www.spandidos-publications.com/10.3892/ol.2021.12860
7. “PNC-27 peptide enhances the antitumor effects of gemcitabine in pancreatic cancer cells” by Wu et al. (2019) published in the journal Oncology Letters. URL: https://www.spandidos-publications.com/10.3892/ol.2019.10914

These studies suggest that PNC-27 has potential anti-cancer properties and may be a promising therapeutic agent for various types of cancer.